Last update: Oct. 9, 2016


Low Risk for breastfeeding

Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.

Antispasmodic drug with direct effect on intestinal smooth muscle and little anticholinergic effects. Used for treatment of Irritable Bowel Syndrome.

At latest update no published data on excretion into breast milk were found.

Anticholinergic drugs may reduce milk production: take a minimum necessary dose and avoid long-term treatment whenever breastmilk were decreased.


We do not have alternatives for C25H35NO5,HCl.

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

C25H35NO5,HCl is Mebeverine Hydrochloride in Molecular formula.

Is written in other languages:


Main tradenames from several countries containing C25H35NO5,HCl in its composition:


Variable Value Unit
Oral Bioavail. 100 %
Molecular weight 466 daltons
Protein Binding 75 %
Tmax 1 - 3 hours
T1/2 1, 1 - 2,5 hours


  1. AEMPS. Mebeverina. Ficha técnica. 2008 Full text (in our servers)
  2. Stockis A, Guelen PJ, de Vos D. Identification of mebeverine acid as the main circulating metabolite of mebeverine in man. J Pharm Biomed Anal. 2002 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at

e-lactancia is a resource recommended by El Parto Es Nuestro from Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM